Anaprazole - Sihuan Pharmaceutical Holdings Group
Alternative Names: Anaprazole sodium - Sihuan; KBP-3571Latest Information Update: 22 Mar 2022
Price :
$50 *
At a glance
- Originator Sihuan Pharmaceutical Holdings Group
- Class Antiulcers
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Duodenal ulcer
Most Recent Events
- 09 Mar 2023 Sihuan Pharmaceutical Holdings Group completes a phase III trial for Duodenal ulcer in China (PO) (NCT04215653)
- 09 Nov 2022 Xuanzhu Biopharmaceutical plans a phase II trial of Anaprazole in reflux Oesophagitis, In China (PO, Tablet), In December 2022 (NCT05604261)
- 08 Mar 2022 Preregistration for Duodenal ulcer in China (PO)